Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Sniper007on Jan 13, 2013 11:27am
173 Views
Post# 20831379

RE: An Answer to Yoshi's Question.

RE: An Answer to Yoshi's Question.

Thanks to all for the valuable posts.

From what I understand there is no legitimate competition for BTI, is that true?  Are companies that are able to get small molecules accross the BBB not competition and is it possible those companies that are able to so, possibly get larger molecules at some point?  Angiochem can deliver small therapeutics across the BBB but why did Angiochem get a 30 million deal with GSK and up to 300mil upon reaching milestone?  It is the belief of IR that the Angiochem program will be unsuccessful.  Angiochem got a cheque but why didn't GSK do a deal with BTI?  GSK knows about BTI.  I'm sure the deal would have been the same with BTI but BTI has shown they can deliver huge quantities across the BBB.  I don't get it.  I would love someone to comment on this.

Allegedly BTI is on all BBB boards in the world and there is allegedly have no perceived competition.  I assume this is the delivery of large molecules.

Has anyone researched the Kayaker post about using modified sugar get get across the BBB?

 

Bullboard Posts